With a little help from pharma friends: Psychedelics for psychiatric therapy

Eli Lilly's acquisition signals a return of psychedelic drugs for mental health. These compounds offer a new approach to rewiring neural connections in the brain. The US FDA has granted breakthrough designations for several psychedelic treatments. Clinical trials are investigating these therapies for various mental health conditions. Indian pharmaceutical companies could explore opportunities in this emerging market.